AR046394A1 - Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen. - Google Patents
Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen.Info
- Publication number
- AR046394A1 AR046394A1 ARP040102527A ARP040102527A AR046394A1 AR 046394 A1 AR046394 A1 AR 046394A1 AR P040102527 A ARP040102527 A AR P040102527A AR P040102527 A ARP040102527 A AR P040102527A AR 046394 A1 AR046394 A1 AR 046394A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cyano
- alkoxy
- halogen
- alkanoyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
Abstract
Composición farmacéutica que comprende un compuesto de fórmula (1), junto con un vehículo o excipiente farmacéuticamente aceptable, y procedimiento para preparar esta composición farmacéutica. Reivindicación 1: Un compuesto de quinolina y quinazolina caracterizado porque tiene la fórmula (1) o una sal farmacéuticamente aceptable del mismo, en la que: R1 es halógeno, ciano, alquilo C1-6, alcoxi C1-6, haloalcoxi C1-6 o haloalquilo C1-6; m es 0, 1, 2, 3 ó 4; X es N o CH; R2 es halógeno, ciano, alquilo C1-6, alcoxi C1-6, haloalcoxi C1-6 o haloalquilo C1-6; n es 0, 1 ó 2; W es -CH2-, -CH(alquilo C1-6)- o -C(alquilo C1-6)(alquilo C1-6)-; p es 0, 1, 2 ó 3; Y y Z juntos forman un grupo cicloalquileno C3-7, o Y es -CH2-, -CH(alquilo C1- 6)- o -C(alquilo C1-6)(alquilo C1-6) y Z es -CH2-, -CHOH-, -CHR6- o -CR6R7- (en el que R6 y R7 son independientemente halógeno, ciano, alquilo C1-6 o alcoxi C1-6); R3 y R4 son independientemente hidrógeno, alquilo C1-6, alquil C1-6sulfonilo o un grupo que tiene la fórmula (2), en la que: r es 0, 1, 2, 3 ó 4; A es oxígeno o azufre; B es un enlace simple o -NR8- (en el que R8 es hidrógeno, arilo o alquilo C1-6, en el que el arilo está opcionalmente sustituido por uno o más sustituyentes independientemente seleccionados entre halógeno, oxo, alquilo C1-6, CF3, ciano, hidroxi, alcanoilo C1-6 y alcoxi C1-6); D es -(CH2)t-, -(CH2)tO- o -O(CH2)t-, en el que t es 0, 1, 2, 3 ó 4; y E es alquilo C1-6, haloalquilo C1-6, cicloalquilo C3-7 (opcionalmente sustituido por uno o más sustituyentes independiente seleccionados entre halógeno, hidroxi, oxo, alquilo C1-6, ciano, CF3, OCF3, alcoxi C1-6 y alcanoilo C1-6), arilo (opcionalmente sustituido por uno o más sustituyentes independientemente seleccionados entre halógeno, oxo, alquilo C1-6, CF3, ciano, hidroxi, alcanoilo C1-6 y alcoxi C1-6), o E es -NR9R10, en el que R9 y R10 se seleccionan independientemente entre hidrógeno, alquilo C1-6 y arilo (opcionalmente sustituido por uno o más sustituyentes independientemente seleccionados entre halógeno, oxo, alquilo C1-6, -CF3, ciano, hidroxi, alcanoilo C1-6 y alcoxi C1-6); o R3 y R4, juntos con el átomo de nitrógeno al que están acoplados R3 y R4, forman un grupo heterocíclico de 3-7 miembros monocíclico o un grupo heterocíclico de 8-11 miembros bicíclico, en el que cada grupo está opcionalmente sustituido por uno o más sustituyentes seleccionados entre halógeno, oxo, alquilo C1-6, ciano, CF3, alcoxi C1-6, alcanoilo C1-6, arilo y arilalquilo C1-6 (en el que el arilo y el arilalquilo C1-6 están además opcionalmente sustituidos por uno o más de halógeno, oxo, alquilo C1-6, ciano, CF3, alcoxi C1-6 o alcanoilo C1-6); y R5 es independientemente halógeno, ciano, alquilo C1-6 o alcoxi C1-6; y q es 0, 1, 2, 3 ó 4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0316915.8A GB0316915D0 (en) | 2003-07-18 | 2003-07-18 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR046394A1 true AR046394A1 (es) | 2005-12-07 |
Family
ID=27764115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040102527A AR046394A1 (es) | 2003-07-18 | 2004-07-16 | Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen. |
Country Status (29)
Country | Link |
---|---|
US (5) | US7279481B2 (es) |
EP (3) | EP1876174B1 (es) |
JP (1) | JP2006528146A (es) |
KR (1) | KR20060041242A (es) |
CN (1) | CN100441571C (es) |
AR (1) | AR046394A1 (es) |
AT (2) | ATE448205T1 (es) |
AU (1) | AU2004263268B2 (es) |
BR (1) | BRPI0412695A (es) |
CA (1) | CA2532452A1 (es) |
CY (1) | CY1107974T1 (es) |
DE (2) | DE602004024141D1 (es) |
DK (1) | DK1646613T3 (es) |
ES (2) | ES2336148T3 (es) |
GB (1) | GB0316915D0 (es) |
HK (1) | HK1089438A1 (es) |
HR (1) | HRP20080226T3 (es) |
IL (1) | IL173036A0 (es) |
IS (1) | IS2744B (es) |
MA (1) | MA27926A1 (es) |
MX (1) | MXPA06000716A (es) |
NO (1) | NO20060774L (es) |
NZ (1) | NZ544586A (es) |
PL (1) | PL1646613T3 (es) |
PT (1) | PT1646613E (es) |
RU (1) | RU2402533C2 (es) |
SI (1) | SI1646613T1 (es) |
TW (1) | TW200521115A (es) |
WO (1) | WO2005014552A1 (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0316915D0 (en) * | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
DK1765327T3 (da) * | 2004-06-17 | 2014-11-03 | Cytokinetics Inc | Forbindelser, sammensætninger og fremgangsmåder |
KR100817538B1 (ko) * | 2006-07-05 | 2008-03-27 | 한국화학연구원 | 신규 치환된―1h―퀴나졸린―2,4―디온 유도체, 이의제조방법 및 이를 함유하는 약학적 조성물 |
US20100041689A1 (en) * | 2006-12-19 | 2010-02-18 | University Of Virginia Patent Foundation | Combined Effects of Topiramate and Ondansetron on Alcohol Consumption |
CA2677205A1 (en) * | 2007-01-31 | 2008-08-07 | University Of Virginia Patent Foundation | Topiramate plus naltrexone for the treatment of addictive disorders |
ES2359170T3 (es) | 2007-07-19 | 2011-05-19 | Laboratorios Del Dr. Esteve S.A. | Compuestos tetrahidro-quinolín-sulfonamida sustituidos, su preparación y uso como medicamentos. |
US20110065628A1 (en) * | 2007-08-27 | 2011-03-17 | University Of Virginia Patent Foundation | Medication Combinations for the Treatment of Alcoholism and Drug Addiction |
JP2011515076A (ja) * | 2008-02-28 | 2011-05-19 | ユニバーシティ オブ バージニア パテント ファウンデーション | セロトニン輸送体遺伝子およびアルコール中毒症の処置 |
JP2011518836A (ja) | 2008-04-24 | 2011-06-30 | インサイト・コーポレイション | 大環状化合物およびそれらのキナーゼ阻害剤としての使用 |
EP2298199B1 (en) * | 2008-05-06 | 2012-05-23 | Biedermann Technologies GmbH & Co. KG | Rod-shaped implant, in particular for the dynamic stabilization of the spine |
US20100298397A1 (en) * | 2009-05-19 | 2010-11-25 | Singh Nikhilesh N | Method of treatment of obsessive compulsive disorder with ondansetron |
CN101671336B (zh) | 2009-09-23 | 2013-11-13 | 辽宁利锋科技开发有限公司 | 芳杂环并嘧啶衍生物和类似物及其制备方法和用途 |
EP2308850A1 (en) * | 2009-10-06 | 2011-04-13 | Laboratorios Del. Dr. Esteve, S.A. | Heterocycyl-substituted-alkylamino phenyl derivatives, their preparation and use as medicaments |
DK2801625T3 (en) | 2010-07-02 | 2018-02-05 | Univ Virginia Patent Foundation | Molecular genetic approach to the treatment and diagnosis of alcohol and drug dependence |
KR20140052018A (ko) | 2011-08-09 | 2014-05-02 | 다케다 야쿠힌 고교 가부시키가이샤 | 시클로프로판아민 화합물 |
EP2751137A4 (en) | 2011-09-09 | 2015-06-03 | Univ Virginia Patent Found | MOLECULAR GENETIC APPROACH FOR THE TREATMENT AND DIAGNOSIS OF ALCOHOL DEPENDENCE AND PHARMACODEPPENDANCE |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
JP6345651B2 (ja) * | 2012-05-09 | 2018-06-20 | サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. | ヘテロアリール化合物及びその使用方法 |
CN103508927A (zh) * | 2012-06-25 | 2014-01-15 | 天津药物研究院 | 一种2-甲磺酰氨基二苯醚的制备方法 |
JP6325449B2 (ja) | 2012-10-12 | 2018-05-16 | 武田薬品工業株式会社 | シクロプロパンアミン化合物およびその用途 |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
RU2701861C1 (ru) | 2013-11-20 | 2019-10-02 | Санва Кагаку Кенкюсо Ко., Лтд. | Новое производное 3-азабицикло[3.1.0]гексана и его применение в медицинских целях |
CN106459024B (zh) | 2014-04-11 | 2019-11-05 | 武田药品工业株式会社 | 环丙胺化合物及其用途 |
WO2016075314A1 (fr) | 2014-11-13 | 2016-05-19 | Institut National De La Recherche Agronomique | Identification de facteurs de transcription de yarrowia lipolytica affectant la production de proteines |
FR3028527A1 (fr) | 2014-11-13 | 2016-05-20 | Pivert | Identification de facteurs de transcription de yarrowia lipolytica |
HUE037476T2 (hu) | 2014-12-23 | 2018-08-28 | 4D Pharma Res Ltd | Pirin polipeptid és immunmodulálás |
KR20220151045A (ko) | 2014-12-23 | 2022-11-11 | 4디 파마 리서치 리미티드 | 면역 조정 |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
EA201890050A1 (ru) | 2015-06-15 | 2018-06-29 | 4Д Фарма Рисёрч Лимитед | Композиции, содержащие бактериальные штаммы |
EA201890048A1 (ru) | 2015-06-15 | 2018-06-29 | 4Д Фарма Рисёрч Лимитед | Композиции, содержащие бактериальные штаммы |
ME03511B (me) | 2015-06-15 | 2020-04-20 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
EP3209310B1 (en) | 2015-11-20 | 2018-01-31 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
LT3313423T (lt) | 2016-03-04 | 2019-06-25 | 4D Pharma Plc | Kompozicijos, apimančios bakterinius blautia kamienus, skirtos visceralinio hiperjautrumo gydymui |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
RS61872B1 (sr) | 2017-05-22 | 2021-06-30 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
EP3638271B1 (en) | 2017-06-14 | 2020-10-14 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
AU2018285453B2 (en) | 2017-06-14 | 2020-03-19 | Cj Bioscience, Inc. | Compositions comprising a bacterial strain of the genus Megasphaera and uses thereof |
CN108047143A (zh) * | 2017-12-18 | 2018-05-18 | 刘凤娟 | 一种用于治疗功能性胃肠病的5-羟色胺受体拮抗剂的合成方法 |
DK3814348T3 (da) | 2018-06-27 | 2023-10-30 | Bristol Myers Squibb Co | Substituerede naphthyridinonforbindelser, der er anvendelige som t-celleaktivatorer |
EA202190137A1 (ru) | 2018-06-27 | 2021-05-17 | Бристол-Маерс Сквибб Компани | Нафтиридиноновые соединения для применения в качестве активаторов t-клеток |
AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2641602A (en) | 1950-11-29 | 1953-06-09 | Eastman Kodak Co | 1, 8-dihydroxy-5-nitro-4-hydroxyethylphenyl aminoanthraquinone compounds |
US3992537A (en) | 1971-06-07 | 1976-11-16 | Boehringer Ingelheim Gmbh | Pharmaceutical compositions containing an N-phenyl-imidazolidine-2-one and method of use |
US3975525A (en) | 1971-06-07 | 1976-08-17 | Boehringer Ingelheim Gmbh | N-[4'-Imidazolidinon-(2)-yl-phenethyl]-N'-pyridyl-piperazines and salts thereof |
US3937708A (en) | 1971-06-07 | 1976-02-10 | Boehringer Ingelheim Gmbh | N-phenyl-imidazolidine-1-ones |
JPS5883677A (ja) | 1981-11-11 | 1983-05-19 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体 |
US4891275A (en) * | 1982-10-29 | 1990-01-02 | Norsk Hydro A.S. | Aluminum shapes coated with brazing material and process of coating |
JPS6354363A (ja) | 1986-08-26 | 1988-03-08 | Ss Pharmaceut Co Ltd | キノリン誘導体 |
FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
US4933447A (en) | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
US4891375A (en) | 1988-01-13 | 1990-01-02 | Pfizer Inc. | Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds |
JP2777159B2 (ja) | 1988-12-22 | 1998-07-16 | エーザイ株式会社 | 環状アミン誘導体を含有する医薬 |
GB9300195D0 (en) | 1993-01-06 | 1993-03-03 | Wyeth John & Brother Ltd | Piperazine derivatives |
GB9300194D0 (en) | 1993-01-06 | 1993-03-03 | Wyeth John & Brother Ltd | Piperazine derivatives |
GB9308725D0 (en) | 1993-04-27 | 1993-06-09 | Wyeth John & Brother Ltd | Piperazine derivatives |
SK285119B6 (sk) | 1996-03-29 | 2006-06-01 | Duphar International Research B. V. | Piperazínové a piperidínové zlúčeniny, spôsob ich prípravy, farmaceutické kompozície, ktoré ich obsahujú, a ich použitie |
WO1997041108A1 (en) | 1996-04-30 | 1997-11-06 | Warner-Lambert Company | Substituted piperazines and piperidines as central nervous system agents |
GB2312843A (en) | 1996-05-07 | 1997-11-12 | Merck & Co Inc | Method of treating rheumatoid arthritis |
WO1998025617A1 (en) | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
ATE253058T1 (de) | 1997-09-02 | 2003-11-15 | Duphar Int Res | Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten |
EP0900792B1 (en) | 1997-09-02 | 2003-10-29 | Duphar International Research B.V | Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists |
DK1027336T3 (da) | 1997-10-27 | 2005-01-24 | Neurosearch As | Heteroaryldiazacycloalkaner, deres fremstilling og anvendelse |
JP2002508366A (ja) | 1997-12-12 | 2002-03-19 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | キノリンピペラジンおよびキノリンピペリジン誘導体、それらの製造方法、ならびに複合的5−ht1a、5−ht1bおよび5−ht1d受容体アンタゴニストとしてのそれらの用途 |
UA62015C2 (en) * | 1998-12-28 | 2003-12-15 | Pfizer Prod Inc | Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants) |
CN1158258C (zh) | 1999-06-24 | 2004-07-21 | 东丽株式会社 | 肾上腺素能α1B受体拮抗药 |
ES2234683T3 (es) * | 1999-11-05 | 2005-07-01 | Smithkline Beecham Plc | Derivados de isoquinolina y quinazolina con actividad combinada sobre los receptores 5ht1a, 5ht1b y 5ht1d. |
JP4242643B2 (ja) | 2000-10-26 | 2009-03-25 | スミスクライン ビーチャム ピー エル シー | ベンズオキサジノン誘導体、その製造および使用 |
CA2364211A1 (en) | 2000-12-05 | 2002-06-05 | Phillip Branch Chappell | Combination treatment for depression, anxiety and psychosis |
GB0106419D0 (en) * | 2001-03-15 | 2001-05-02 | Smithkline Beecham Plc | Novel compounds |
UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
GB0203804D0 (en) | 2002-02-18 | 2002-04-03 | Glaxo Group Ltd | Compounds |
GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
WO2004041793A1 (en) | 2002-11-08 | 2004-05-21 | Warner-Lambert Company Llc | Phenylalkyl and pyridylalkyl piperazine derivatives |
GB0227240D0 (en) | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
US6759435B1 (en) * | 2003-07-03 | 2004-07-06 | A.P. Group Inc. | Antidepressant drugs and methods |
GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
US20050124625A1 (en) | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
WO2005087742A1 (en) | 2004-03-08 | 2005-09-22 | Exelixis, Inc. | Metabolic kinase modulators and methods of use as pesticides |
AU2005221832A1 (en) | 2004-03-10 | 2005-09-22 | Nycomed Gmbh | Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors |
PE20060653A1 (es) | 2004-08-31 | 2006-09-27 | Glaxo Group Ltd | Derivados triciclicos condensados como moduladores del receptor 5-ht1 |
-
2003
- 2003-07-18 GB GBGB0316915.8A patent/GB0316915D0/en not_active Ceased
-
2004
- 2004-07-15 WO PCT/EP2004/008000 patent/WO2005014552A1/en active IP Right Grant
- 2004-07-15 KR KR1020067001103A patent/KR20060041242A/ko not_active Application Discontinuation
- 2004-07-15 ES ES07118193T patent/ES2336148T3/es active Active
- 2004-07-15 RU RU2006104993/04A patent/RU2402533C2/ru not_active IP Right Cessation
- 2004-07-15 ES ES04763307T patent/ES2302543T3/es active Active
- 2004-07-15 DE DE602004024141T patent/DE602004024141D1/de active Active
- 2004-07-15 DE DE602004012564T patent/DE602004012564T2/de active Active
- 2004-07-15 US US10/565,066 patent/US7279481B2/en not_active Expired - Fee Related
- 2004-07-15 EP EP07118193A patent/EP1876174B1/en active Active
- 2004-07-15 EP EP04763307A patent/EP1646613B1/en active Active
- 2004-07-15 AT AT07118193T patent/ATE448205T1/de not_active IP Right Cessation
- 2004-07-15 CN CNB2004800270575A patent/CN100441571C/zh not_active Expired - Fee Related
- 2004-07-15 SI SI200430699T patent/SI1646613T1/sl unknown
- 2004-07-15 BR BRPI0412695-5A patent/BRPI0412695A/pt not_active IP Right Cessation
- 2004-07-15 JP JP2006520756A patent/JP2006528146A/ja not_active Ceased
- 2004-07-15 EP EP09175186A patent/EP2145622A1/en not_active Withdrawn
- 2004-07-15 DK DK04763307T patent/DK1646613T3/da active
- 2004-07-15 AU AU2004263268A patent/AU2004263268B2/en not_active Ceased
- 2004-07-15 MX MXPA06000716A patent/MXPA06000716A/es active IP Right Grant
- 2004-07-15 NZ NZ544586A patent/NZ544586A/en unknown
- 2004-07-15 CA CA002532452A patent/CA2532452A1/en not_active Abandoned
- 2004-07-15 PT PT04763307T patent/PT1646613E/pt unknown
- 2004-07-15 AT AT04763307T patent/ATE389637T1/de active
- 2004-07-15 PL PL04763307T patent/PL1646613T3/pl unknown
- 2004-07-16 AR ARP040102527A patent/AR046394A1/es not_active Application Discontinuation
- 2004-07-16 TW TW093121227A patent/TW200521115A/zh unknown
-
2006
- 2006-01-09 IL IL173036A patent/IL173036A0/en unknown
- 2006-01-18 MA MA28738A patent/MA27926A1/fr unknown
- 2006-02-15 IS IS8304A patent/IS2744B/is unknown
- 2006-02-17 NO NO20060774A patent/NO20060774L/no not_active Application Discontinuation
- 2006-09-01 HK HK06109772A patent/HK1089438A1/xx not_active IP Right Cessation
-
2007
- 2007-03-16 US US11/687,098 patent/US7459456B2/en not_active Expired - Fee Related
-
2008
- 2008-05-23 HR HR20080226T patent/HRP20080226T3/xx unknown
- 2008-05-29 CY CY20081100555T patent/CY1107974T1/el unknown
- 2008-07-02 US US12/166,547 patent/US7592346B2/en not_active Expired - Fee Related
-
2009
- 2009-08-13 US US12/540,452 patent/US7732600B2/en not_active Expired - Fee Related
-
2010
- 2010-04-23 US US12/766,053 patent/US20100204273A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR046394A1 (es) | Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen. | |
AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
AR109958A1 (es) | Lactamas bicíclicas de piridona y sus métodos de uso | |
CO6160229A2 (es) | Ciclopenta [d] pirimidinas como inhibidores de proteina quinasa akt | |
AR063601A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
AR049443A1 (es) | Derivados de pirrolpiridinas | |
AR077434A1 (es) | Compuestos para la reduccion de produccion de beta - amiloide | |
AR038235A1 (es) | Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1 | |
AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
AR060173A1 (es) | Derivados de piridina y de pirimidina como antagonistas del mglur2, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos del snc. | |
AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
AR044011A1 (es) | Antagonistas de mchr1 heterociclicos | |
AR052215A1 (es) | 3-aminociclopentancarboxamidas como moduladores de receptores de quimioquinas, su uso en el tratamiento de enfermedades relacionadas y composiciones farmacéuticas que las contienen. | |
AR019115A1 (es) | Derivados de la 1-[(1-sustituido-4-piperidinil)metil]-4-piperidina, procesos para la preparacion de los mismos, composiciones farmaceuticas que loscontienen y los compuestos intermedios para prepararlos | |
AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
AR045931A1 (es) | Derivados de piperazina | |
AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
AR064414A1 (es) | Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que | |
AR044134A1 (es) | Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas. | |
AR041246A1 (es) | Derivados de piridina; un procedimiento de preparacion de los mismos y composicion farmaceutica que los contiene | |
AR046085A1 (es) | Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico | |
AR069814A1 (es) | Derivados de 4 amino-pirimidina, proceso de preparacion y composiciones farmaceuticas que los contienen | |
CO5650235A2 (es) | Derivados de imidazol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |